BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

"I think we can see light at the end of the tunnel" on the pandemic, Pfizer's Albert Bourla told CNBC on Monday.

Pfizer CEO calls Covid vaccine a 'great day for humanity' and a 'light at the end of the tunnel'

The coronavirus vaccine developed by Pfizer and BioNTech is more than 90 percent effective, the companies said Monday in a major milestone for the fight against the deadly global pandemic. The Manhattan-based drugmaker and the German biotech firm became the first pharmaceutical outfits to reveal successful data from a large, late-stage study of a COVID-19.

Pfizer's COVID-19 vaccine is more than 90 percent effective, company says

So far the vaccine has been tested on 43,500 people in six countries, with no safety concerns raised.

First COVID vaccine offers 90% protection, drug company claims

Global stocks surged to record highs after Pfizer on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19, based on initial data from a large study.

Instant View: Global stocks soar on Pfizer, Biontech vaccine news

Pfizer leapt 13% in pre-market trading on Monday after the drugmaker announced that its experimental COVID-19 vaccine succeeded in late-stage trials. The US pharma firm said its vaccine, developed with German biotech partner BioNTech, is over 90% effective in preventing COVID-19 infection.

Pfizer leaps 13% on news that its COVID-19 vaccine is over 90% effective in preventing illness

The COVID-19 vaccine being developed by Pfizer and its partner BioNTech has shown to be effective blocking vaccine in 90 percent of participants in its Phase 3 clinical trial, the companies announced on Monday. That's based on data analyzed by an external, independent committee assigned to check the results of the trial, and reflects only […]

Pfizer's COVID-19 vaccine proves 90% effective in first results from Phase 3 clinical trial

The coronavirus vaccine being developed by Pfizer and BioNTech has been found to be 90% effective in preventing people from getting the virus, it has been confirmed.

COVID-19 vaccine found to be 90% effective in 'great day for science and humanity'

Shares of Germany-based BioNTech SE shot up 17.9% and Pfizer Inc. jumped 8.6% in premarket trading Monday, after the company's said their COVID-19 vaccine candidate achieved "success" in the first interim analysis of from a Phase 3 study. The companies said BNT162b2 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in trial participants without previous evidence of SARS-CoV-2 infection.

BioNTech, Pfizer stocks soar after COVID-19 vaccine candidate achieves 'success' in first analysis

A leading coronavirus vaccine candidate worked to prevent people from developing COVID-19, a milestone in society's war against the pandemic. The pharmaceutical company Pfizer said Monday that its vaccine succeeded in the final stage of clinical trials, which compared tens of thousands of volunteers who received two doses of the experimental vaccine against a group receiving a saltwater placebo.

Pfizer says its coronavirus vaccine helps prevent COVID-19, marking a milestone in the fight against the pandemic

Interim analysis of vaccine by Pfizer/BioNTech far exceeds expectations of most experts

Covid-19 vaccine candidate is 90% effective, says manufacturer

Albert Bourla, chairman and CEO of Pfizer, hailed the development as a "great day for science and humanity."

Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, t

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Inovio Pharmaceuticals

Moderna

The fate of this company's late-stage trial is now in the hands of the FDA.

November Is a Crucial Month for this Coronavirus Vaccine Stock

What Are Your Chances of Getting a Coronavirus Vaccine by Year-End?

AstraZeneca

Novavax

Australia has agreed to purchase another 50 million doses of two more COVID-19 vaccines, Prime Minister Scott Morrison said on Thursday, as Canberra aims to complete a mass inoculation programme within months.

Australia signs two more COVID-19 vaccine deals

On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.

Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?

Mainz, Germany, November 3, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2020 on Tuesday, November 10th, 2020. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 08:00 a.m. EDT (2:00 p.m. CET) to report its financial results and provide a corporate update on the third quarter 2020.

BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020

ACADIA Pharma

Alnylam Pharmaceuticals

AvroBio Inc

Biohaven Pharmaceutical Hld

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

3 Reasons Pfizer and BioNTech's Coronavirus Vaccine Might Fail Even If It Works

The sky is the limit for this biotech company, and not just because of its promising coronavirus vaccine candidate.

What's the Outlook for BioNTech Stock?

One bank in the company's native Germany believes the stock has a rich upside potential of 40%.

Is BioNTech Stock Really Headed to $119?

Moderna and BioNtech surged in Thursday trades as investor focus on a successful COVID-19 vaccine remained heightened amid a surge in daily virus cases. Moderna traded higher by as much as 13%, while BioNtech jumped as much as 11%.

Moderna, BioNtech surge as COVID-19 vaccine development progresses amid virus spike (MRNA)

PFE/BNTX and MRNA remain the front-runners in the race to develop a COVID-19 vaccine. PFE has seen some delays but at least, we haven't passed an interim analysis without success.

Judgement Day Approaches For COVID-19 Vaccine Names

So far, only one late-stage study evaluating a COVID-19 vaccine candidate includes children.

Here's the Clear Leader in Developing a Coronavirus Vaccine for Kids

Sorrento Therapeutics Inc

These two companies don't have recurring revenues to rely on.

News for BioNTech SE Stock (BNTX)